The U.S. Senate Appropriations Committee wants federal healthcare officials to tell it what they have done about drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
The committee included the directive to the U.S. Health Resources and Services Administration (HRSA) in an explanatory statement that accompanies its draft spending bill for labor, health and human services, and education programs for the fiscal year that starts Oct. 1. Committee chair Patrick Leahy (D-Vt.) released the bill and statement on July 28. The panel has not yet scheduled a hearing to mark up the bill.
The U.S. Senate Appropriations Committee wants federal healthcare officials to tell it what they have done about drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
